• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型生物标志物可预测前列腺癌患者的预后和药物诱导的神经内分泌分化。

Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer.

机构信息

Department of Urology & Andrology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

出版信息

Front Endocrinol (Lausanne). 2023 Jan 5;13:1005916. doi: 10.3389/fendo.2022.1005916. eCollection 2022.

DOI:10.3389/fendo.2022.1005916
PMID:36686485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9849576/
Abstract

BACKGROUND

A huge focus is being placed on the development of novel signatures in the form of new combinatorial regimens to distinguish the neuroendocrine (NE) characteristics from castration resistant prostate cancer (CRPC) timely and accurately, as well as predict the disease-free survival (DFS) and progression-free survival (PFS) of prostate cancer (PCa) patients.

METHODS

Single cell data of 4 normal samples, 3 CRPC samples and 3 CRPC-NE samples were obtained from GEO database, and CellChatDB was used for potential intercellular communication, Secondly, using the "limma" package (v3.52.0), we obtained the differential expressed genes between CRPC and CRPC-NE both in single-cell RNA seq and bulk RNA seq samples, and discovered 12 differential genes characterized by CRPC-NE. Then, on the one hand, the diagnosis model of CRPC-NE is developed by random forest algorithm and artificial neural network (ANN) through Cbioportal database; On the other hand, using the data in Cbioportal and GEO database, the DFS and PFS prognostic model of PCa was established and verified through univariate Cox analysis, least absolute shrinkage and selection operator (Lasso) regression and multivariate Cox regression in R software. Finally, somatic mutation and immune infiltration were also discussed.

RESULTS

Our research shows that there exists specific intercellular communication in classified clusters. Secondly, a CRPC-NE diagnostic model of six genes ( and ) has been established and verified, the area under the ROC curve (AUC) is as high as 0.952 (95% CI: 0.882-0.994). The mutation landscape shows that these six genes are rarely mutated in the CRPC and NEPC samples. In addition, NE-DFS signature ( and ) and NE-PFS signature () are good predictors of DFS and PFS in PCa patients and better than other clinical features. Lastly, the infiltration levels of plasma cells, T cells CD4 naive, Eosinophils and Monocytes were significantly different between the CRPC and NEPC groups.

CONCLUSIONS

This study revealed the heterogeneity between CRPC and CRPC-NE from different perspectives, and developed a reliable diagnostic model of CRPC-NE and robust prognostic models for PCa.

摘要

背景

目前的研究重点是开发新的组合方案,以新型组合方案的形式形成新的组合方案,及时、准确地从去势抵抗性前列腺癌(CRPC)中区分神经内分泌(NE)特征,并预测前列腺癌(PCa)患者的无病生存期(DFS)和无进展生存期(PFS)。

方法

从 GEO 数据库中获取 4 个正常样本、3 个 CRPC 样本和 3 个 CRPC-NE 样本的单细胞数据,使用 CellChatDB 进行潜在的细胞间通讯;其次,使用“limma”包(v3.52.0),我们在单细胞 RNA seq 和批量 RNA seq 样本中获得了 CRPC 和 CRPC-NE 之间差异表达的基因,并发现了 12 个具有 CRPC-NE 特征的差异基因。然后,一方面,通过 Cbioportal 数据库,利用随机森林算法和人工神经网络(ANN)建立和验证 CRPC-NE 的诊断模型;另一方面,利用 Cbioportal 和 GEO 数据库的数据,在 R 软件中通过单因素 Cox 分析、最小绝对收缩和选择算子(Lasso)回归和多因素 Cox 回归建立和验证 PCa 的 DFS 和 PFS 预后模型。最后,还讨论了体细胞突变和免疫浸润。

结果

我们的研究表明,在分类簇中存在特定的细胞间通讯。其次,建立并验证了一个由 6 个基因(和)组成的 CRPC-NE 诊断模型,ROC 曲线下面积(AUC)高达 0.952(95%CI:0.882-0.994)。突变景观表明,这 6 个基因在 CRPC 和 NEPC 样本中很少发生突变。此外,NE-DFS 特征(和)和 NE-PFS 特征()是 PCa 患者 DFS 和 PFS 的良好预测因子,优于其他临床特征。最后,CRPC 和 NEPC 组之间浆细胞、T 细胞 CD4 幼稚、嗜酸性粒细胞和单核细胞的浸润水平有显著差异。

结论

本研究从不同角度揭示了 CRPC 和 CRPC-NE 之间的异质性,并开发了一种可靠的 CRPC-NE 诊断模型和稳健的 PCa 预后模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/094508ecd99e/fendo-13-1005916-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/ad0fa2059b7a/fendo-13-1005916-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/2aefb45cc9cb/fendo-13-1005916-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/f3c3083a4b0f/fendo-13-1005916-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/c7f3ba4e208c/fendo-13-1005916-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/aec475f06c94/fendo-13-1005916-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/eb27bd8c4bba/fendo-13-1005916-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/005da85a18ed/fendo-13-1005916-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/d34873d25174/fendo-13-1005916-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/fe7b8fd20664/fendo-13-1005916-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/0e5d43c50139/fendo-13-1005916-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/094508ecd99e/fendo-13-1005916-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/ad0fa2059b7a/fendo-13-1005916-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/2aefb45cc9cb/fendo-13-1005916-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/f3c3083a4b0f/fendo-13-1005916-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/c7f3ba4e208c/fendo-13-1005916-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/aec475f06c94/fendo-13-1005916-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/eb27bd8c4bba/fendo-13-1005916-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/005da85a18ed/fendo-13-1005916-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/d34873d25174/fendo-13-1005916-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/fe7b8fd20664/fendo-13-1005916-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/0e5d43c50139/fendo-13-1005916-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/9849576/094508ecd99e/fendo-13-1005916-g011.jpg

相似文献

1
Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer.新型生物标志物可预测前列腺癌患者的预后和药物诱导的神经内分泌分化。
Front Endocrinol (Lausanne). 2023 Jan 5;13:1005916. doi: 10.3389/fendo.2022.1005916. eCollection 2022.
2
Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.鉴定治疗相关性神经内分泌前列腺癌的新型诊断生物标志物。
Pathol Oncol Res. 2021 Sep 27;27:1609968. doi: 10.3389/pore.2021.1609968. eCollection 2021.
3
Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancer.靶向SOX4/PCK2信号通路可抑制去势抵抗性前列腺癌的神经内分泌转分化。
Biol Direct. 2024 Jul 16;19(1):56. doi: 10.1186/s13062-024-00500-2.
4
A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data.使用 bulk 和单细胞测序数据的联合分析生成的 12 基因panel 可用于预测去势抵抗性前列腺癌患者的激素治疗反应。
Ann Med. 2023;55(2):2260387. doi: 10.1080/07853890.2023.2260387. Epub 2023 Sep 20.
5
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.原发性前列腺癌中预先存在的去势抵抗性前列腺癌细胞样细胞促进对激素治疗的抵抗。
Eur Urol. 2022 May;81(5):446-455. doi: 10.1016/j.eururo.2021.12.039. Epub 2022 Jan 17.
6
and are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine.和 是前列腺癌进展和多柔比星耐药的去势抵抗性前列腺癌的关键基因。
Front Endocrinol (Lausanne). 2022 Dec 19;13:1106175. doi: 10.3389/fendo.2022.1106175. eCollection 2022.
7
Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.激素敏感性前列腺癌和去势抵抗性前列腺癌中雄激素受体变异体7和泛素结合酶2C的转录水平
Prostate. 2017 Jan;77(1):60-71. doi: 10.1002/pros.23248. Epub 2016 Aug 22.
8
Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer.血浆外泌体蛋白和代谢物的改变与去势抵抗性前列腺癌的进展相关。
J Transl Med. 2023 Jan 21;21(1):40. doi: 10.1186/s12967-022-03860-3.
9
Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.用于检测去势抵抗性前列腺癌患者治疗诱导的神经内分泌分化的新型非侵入性标志物。
Sci Rep. 2021 Apr 15;11(1):8279. doi: 10.1038/s41598-021-87441-2.
10
Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.治疗后出现的神经内分泌前列腺癌:94例临床病理及免疫组化分析
Front Oncol. 2021 Feb 1;10:571308. doi: 10.3389/fonc.2020.571308. eCollection 2020.

引用本文的文献

1
Neoadjuvant PD-1 blockade induces the autophagy of immune cells: a new target for synergistic therapy of recurrent glioblastoma.新辅助PD-1阻断诱导免疫细胞自噬:复发性胶质母细胞瘤协同治疗的新靶点。
Biochem Biophys Rep. 2025 Jun 27;43:102119. doi: 10.1016/j.bbrep.2025.102119. eCollection 2025 Sep.
2
Identifying MSMO1, ELOVL6, AACS, and CERS2 related to lipid metabolism as biomarkers of Parkinson's disease.鉴定与脂质代谢相关的 MSMO1、ELOVL6、AACS 和 CERS2 作为帕金森病的生物标志物。
Sci Rep. 2024 Jul 30;14(1):17478. doi: 10.1038/s41598-024-68585-3.
3
[Dynamic trajectory and cell communication of different cell clusters in malignant progression of glioblastoma].

本文引用的文献

1
Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer.神经内分泌前列腺癌的单细胞转录调控与遗传进化
iScience. 2022 Jun 13;25(7):104576. doi: 10.1016/j.isci.2022.104576. eCollection 2022 Jul 15.
2
MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway.MLLT11-TRIL 复合物通过 PI3K/AKT/mTOR 信号通路促进子宫内膜癌的进展。
Cancer Biol Ther. 2022 Dec 31;23(1):211-224. doi: 10.1080/15384047.2022.2046450.
3
Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma.
[胶质母细胞瘤恶性进展中不同细胞簇的动态轨迹与细胞通讯]
Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Apr 18;56(2):199-206. doi: 10.19723/j.issn.1671-167X.2024.02.001.
4
Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis.基于多组学分析鉴定细胞分化轨迹相关基因特征以揭示前列腺癌的预后意义和免疫格局
Heliyon. 2024 Mar 8;10(6):e27628. doi: 10.1016/j.heliyon.2024.e27628. eCollection 2024 Mar 30.
5
Aggrephagy-related patterns in tumor microenvironment, prognosis, and immunotherapy for acute myeloid leukemia: a comprehensive single-cell RNA sequencing analysis.急性髓系白血病肿瘤微环境、预后及免疫治疗中的聚集吞噬相关模式:一项全面的单细胞RNA测序分析
Front Oncol. 2023 Jul 17;13:1195392. doi: 10.3389/fonc.2023.1195392. eCollection 2023.
单细胞转录组学将恶性 T 细胞与皮肤 T 细胞淋巴瘤中的肿瘤免疫图谱联系起来。
Nat Commun. 2022 Mar 3;13(1):1158. doi: 10.1038/s41467-022-28799-3.
4
Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.单细胞分析人类原发性前列腺癌揭示了肿瘤相关上皮细胞状态的异质性。
Nat Commun. 2022 Jan 10;13(1):141. doi: 10.1038/s41467-021-27322-4.
5
Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.鉴定治疗相关性神经内分泌前列腺癌的新型诊断生物标志物。
Pathol Oncol Res. 2021 Sep 27;27:1609968. doi: 10.3389/pore.2021.1609968. eCollection 2021.
6
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.clusterProfiler 4.0:用于解释组学数据的通用富集工具。
Innovation (Camb). 2021 Jul 1;2(3):100141. doi: 10.1016/j.xinn.2021.100141. eCollection 2021 Aug 28.
7
Tumor-Associated Macrophage Promotes the Survival of Cancer Cells upon Docetaxel Chemotherapy via the CSF1/CSF1R-CXCL12/CXCR4 Axis in Castration-Resistant Prostate Cancer.肿瘤相关巨噬细胞通过 CSF1/CSF1R-CXCL12/CXCR4 轴促进多西他赛化疗后去势抵抗性前列腺癌中癌细胞的存活。
Genes (Basel). 2021 May 19;12(5):773. doi: 10.3390/genes12050773.
8
Integrated analysis of multimodal single-cell data.多模态单细胞数据的综合分析。
Cell. 2021 Jun 24;184(13):3573-3587.e29. doi: 10.1016/j.cell.2021.04.048. Epub 2021 May 31.
9
Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.一种新型治疗相关神经内分泌前列腺癌细胞系KUCaP13的建立与鉴定
Cancer Sci. 2021 Jul;112(7):2781-2791. doi: 10.1111/cas.14935. Epub 2021 Jun 1.
10
Optimizing the diagnosis and management of ductal prostate cancer.优化导管前列腺癌的诊断和管理。
Nat Rev Urol. 2021 Jun;18(6):337-358. doi: 10.1038/s41585-021-00447-3. Epub 2021 Apr 6.